...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >Serum HER-2: Sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients
【24h】

Serum HER-2: Sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients

机译：血清HER-2：检测乳腺癌患者转移复发的敏感性，特异性和预测价值

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: The aim of this study was to determine the sensitivity, specificity, and predictive values of serum HER-2 for detecting metastatic recurrence in breast cancer patients. Methods: In the period 2004-2009, serum HER-2 was measured in 1,348 patients with breast cancer: 837 during routine controls at the Oncology Department and 511 newly diagnosed. The patients with positive serum HER-2, all the newly diagnosed and 1/5 of the patients with negative serum HER-2 were followed with serum HER-2 measurements every 3-12 months using the ADVIA Centaur assay. Tissue HER-2 status was determined by IHC and FISH. Patients with a single serum HER-2 value above 15 μg/L were considered serum positive. Metastases were diagnosed according to the routine clinical methods using imaging/biopsy. Results: Of the 862 patients included, 21 had unavailable medical records and were excluded. Patients with unknown tissue status (218), missing blood sample before recurrence (74), or presenting with primary metastatic disease (9) were also excluded. Blood samples before the detection of metastatic recurrence were available in 154 tissue HER-2-positive and in 386 tissue HER-2-negative patients. The sensitivity, specificity, positive and negative predictive values in tissue HER-2-positive patients with values above 15 μg/L were 69 % (95 % CI 53-80 %), 71 % (62-78), 47 % (35-59), and 86 % (77-91), respectively. Combining the cutoff value of 15 μg/L with a delta value of >100 % increase from individual baseline after primary therapy, or increasing the cutoff to 32 μg/L raises the specificity to 96 %, but lowers the sensitivity to 50 and 47 %, respectively. Preoperative serum HER-2 values were accessible in 69 tissue-positive patients, but no significant association was found with later development of metastases. The sensitivity, specificity, positive and negative predictive values in tissue HER-2-negative patients with values above 15 μg/L were 33 % (21-47), 77 % (73-82), 18 % (12-27), and 88 % (84-91), respectively. Conclusions: Monitoring tissue HER-2-positive breast cancer patients with serum HER-2 has a sufficient sensitivity to detect metastatic recurrence, while its use in monitoring of tissue HER-2-negative patients is unsatisfactory.
机译：目的：本研究的目的是确定血清HER-2检测乳腺癌患者转移复发的敏感性，特异性和预测价值。方法：在2004-2009年期间，对1,348例乳腺癌患者进行了血清HER-2检测：在肿瘤科的常规对照中为837例，新诊断为511例。血清HER-2阳性的患者，所有新诊断的患者以及血清HER-2阴性的患者的1/5，每3-12个月使用ADVIA Centaur测定法进行血清HER-2测量。组织HER-2的状态由IHC和FISH确定。单一血清HER-2值高于15μg/ L的患者被视为血清阳性。使用成像/活检根据常规临床方法诊断转移灶。结果：在862名患者中，有21名患者没有可用的医疗记录，被排除在外。组织状态未知（218），复发前血样丢失（74）或原发转移性疾病（9）的患者也被排除在外。在154例组织HER-2阳性和386例组织HER-2阴性患者中，可检测到转移性复发之前的血样。 ≥15μg/ L的组织HER-2阳性患者的敏感性，特异性，阳性和阴性预测值分别为69％（95％CI 53-80％），71％（62-78），47％（35 -59）和86％（77-91）。将15μg/ L的临界值与一次治疗后相对于单个基线的增量值> 100％的增量相结合，或将临界值增加至32μg/ L，可将特异性提高至96％，但将敏感性降低至50和47％ ， 分别。术前血清HER-2值可在69名组织阳性患者中获得，但与转移灶的后期发展无显着相关性。在组织HER-2阴性的15μg/ L以上的患者中，其敏感性，特异性，阳性和阴性预测值分别为33％（21-47），77％（73-82），18％（12-27），和88％（84-91）。结论：用血清HER-2监测组织HER-2阳性的乳腺癌患者具有足够的敏感性检测转移性复发，而其在监测组织HER-2阴性患者中的使用效果不理想。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号